Get the Stockscreener App
1.665
2.06%
-0.035
After Hours:
1.70
0.035
+2.10%
Inmune Bio Inc stock is traded at $1.665, with a volume of 625.29K.
It is down -2.06% in the last 24 hours and up +32.14% over the past month.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
See More
Previous Close:
$1.70
Open:
$1.7
24h Volume:
625.29K
Relative Volume:
1.02
Market Cap:
$44.26M
Revenue:
$50,000
Net Income/Loss:
$-41.60M
P/E Ratio:
-0.9825
EPS:
-1.6946
Net Cash Flow:
$-20.20M
1W Performance:
+2.78%
1M Performance:
+32.14%
6M Performance:
+6.73%
1Y Performance:
-34.19%
1-Day Range:
$1.65
$1.745
1-Week Range:
$1.58
$1.745
52-Week Range:
$1.09
$3.244
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.665 | 43.33M | 50,000 | -41.60M | -20.20M | -1.6946 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
INmune Bio Inc. Announces Warrant Inducement Offer and Amendment to April 2024 Warrants – Key Details from Latest 8-K Filing – Minichart - Minichart
INmune Bio Executes Warrant Inducement and Extension Agreement - TipRanks
INMB Seeks Patent Approval for CORDStrom Platform - GuruFocus
INmune Bio files U.S. patent for cell therapy platform - Investing.com
Inmune Bio Raises ~$0.9M Via $1.40 Warrant Inducement, Extends Remaining Warrants to 2027 - TradingView
INmune Bio (NASDAQ: INMB) cuts warrant price, extends 2027 expiry - Stock Titan
INmune Bio files U.S. patent for cell therapy platform By Investing.com - Investing.com Canada
INmune Bio moves CORDStrom into U.S. patent review - Stock Titan
Price to sales forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
Price to earnings forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM:INMB) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Growth Benchmark - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Dynamic Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) added to Russell Microcap Value Benchmark Index - marketscreener.com
Enterprise value to EBIT forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2500 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 2000 Index - marketscreener.com
INmune Bio Inc.(NasdaqCM: INMB) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of INmune Bio Inc. – NASDAQ:INMB - TradingView
INmune Bio Inc (INMB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
INmune Bio, Inc. Actuals & Estimates (NASDAQ:INMB) - TradingView
INMB Forecast — Price Target — Prediction for 2027 - TradingView
INMB Secures UK Regulatory Approval for Pediatric Treatment Plan - GuruFocus
INmune Bio receives UK regulatory approval for RDEB treatment plan - Investing.com
INmune Bio receives UK regulatory approval for RDEB treatment plan By Investing.com - Investing.com Canada
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ - The Manila Times
INmune Bio clears key UK pediatric review for Ebstrocel in RDEB - Stock Titan
INmune Bio Inc (INMB) Institutional Confidence - TradingKey
INmune Bio Advances Ebstrocel Toward UK Conditional Approval - TipRanks
MHRA backs INmune Bio (NASDAQ: INMB) plan for 2026 UK CORDStrom filing - Stock Titan
INMB Receives Regulatory Guidance for CORDStrom in Epidermolysis Bullosa - GuruFocus
INmune Bio receives MHRA alignment for RDEB therapy filing - Investing.com
INmune Bio's CORDStrom Gets Written Alignment on UK Conditional Marketing Authorization Application - marketscreener.com
INmune Bio receives MHRA alignment for RDEB therapy filing By Investing.com - Investing.com India
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB - The Manila Times
INmune Bio wins MHRA backing for 2026 UK rare-disease filing - Stock Titan
INmune Bio Inc (INMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Inmune Bio focuses on Alzheimer’s data, shares on NASDAQ in a volatile biotech niche - AD HOC NEWS
INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform - BioInformant
INmune Bio Inc (INMB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
INmune Bio Inc (INMB) Valuation: PE, PB & Fair Value Analysis - TradingKey
INmune Bio Inc (INMB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
INmune Bio Inc (INMB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
INmune Bio Inc (INMB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
INmune Bio Inc (INMB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inmune Bio Shareholders Reaffirm Board, Auditor and Incentive Plan - TipRanks
INmune Bio (INMB) holders OK larger stock plan and evergreen share increases - Stock Titan
INMB Q4 2025 Earnings: EPS Surprise of 24.6% Highlights Operational ProgressNon-GAAP Earnings - newsline.com
INMB Q4 2025 Earnings: EPS Beat Surprises Street as Clinical Pipeline AdvancesTax Rate Impact - newsline.com
Maxim Group Maintains INmune Bio(INMB.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):